Puoti C, Magrini A, Filippi T, Annovazzi G, Pannullo A
Liver Unit, Marino General Hospital, Rome, Italy.
Eur J Gastroenterol Hepatol. 1995 Feb;7(2):151-4.
To study the effect of ursodeoxycholic acid (UDCA) on serum liver enzyme levels [alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT)] in 101 patients with hepatitis C virus-related chronic liver disease.
Forty-nine patients were assigned to receive UDCA (450 mg/day) over a period of 6 months and 52 to receive no treatment.
In the UDCA group, serum ALT and GGT levels significantly improved. ALT values decreased from pre-treatment levels of 157.0 +/- 62.6 IU/l to 82.5 +/- 46.4 IU/l (P < 0.05), and GGT fell from 141.3 +/- 86.2 IU/l to 66.0 +/- 49.5 IU/l (P < 0.001). No significant change occurred in the mean ALT and GGT levels in the control group.
Although our encouraging preliminary results must be validated by double-blind histological trials, UDCA may be an alternative treatment for patients who fail to respond to interferon therapy.
研究熊去氧胆酸（UDCA）对101例丙型肝炎病毒相关性慢性肝病患者血清肝酶水平[丙氨酸氨基转移酶（ALT）和γ-谷氨酰转移酶（GGT）]的影响。
49例患者被分配接受UDCA（450毫克/天）治疗6个月，52例患者不接受治疗。
在UDCA组中，血清ALT和GGT水平显著改善。ALT值从治疗前的157.0±62.6国际单位/升降至82.5±46.4国际单位/升（P<0.05），GGT从141.3±86.2国际单位/升降至66.0±49.5国际单位/升（P<0.001）。对照组的平均ALT和GGT水平无显著变化。
尽管我们令人鼓舞的初步结果必须通过双盲组织学试验进行验证，但UDCA可能是对干扰素治疗无反应患者的一种替代治疗方法。
